close
Add to watchlist
RXi Pharmaceuticals Corp (RXII)
RXi Pharmaceuticals Corporation, a discovery-stage biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on RNA interference for the treatment of human diseases in the United States and internationally. It intends to identify lead compounds and advance towards pre-clinical and clinical development programs in various therapeutic areas, including inflammatory disease; and metabolic diseases, such as obesity and obesity-related type 2 diabetes. The company was formerly known as Argonaut Pharmaceuticals, Inc. and changed its name to RXi Pharmaceuticals Corporation in 2006 before beginning operations in 2007. RXi Pharmaceuticals was founded in 2003 and is based in Worcester, Massachusetts.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 0.80 |
| Volume | 173394 |
| Volume Avg | 498485 |
| 52 Week High | 4.08 |
| 52 Week Low | 0.61 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -0.47 |
| EPS change Q/Q | -90% |
| EPS change Q/Q Yr ago | -20.83% |
| EPS change Q/Q next Q est | -5% |
| EPS change Y/Y | -84.38% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | -0.20 |
| EPS next Y est | -0.43 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |